Predicting the Fluency of Text with Shallow Structural Features: Case Studies of Machine Tanslation and Human-Written Text

Sentence fluency is an important component of overall text readability but few studies in natural language processing have sought to understand the factors that define it. We report the results of an initial study into the predictive power of surface syntactic statistics for the task; we use fluency assessments done for the purpose of evaluating machine translation. We find that these features are weakly but significantly correlated with fluency. Machine and human translations can be distinguished with accuracy over 80%. The performance of pairwise comparison of fluency is also very high—over 90% for a multi-layer perceptron classifier. We also test the hypothesis that the learned models capture general fluency properties applicable to human-written text. The results do not support this hypothesis: prediction accuracy on the new data is only 57%. This finding suggests that developing a dedicated, task-independent corpus of fluency judgments will be beneficial for further investigations of the problem

Structural Features for Predicting the Linguistic Quality of Text: Applications to Machine Translation, Automatic Summarization and Human-Authored Text

Sentence structure is considered to be an important component of the overall linguistic quality of text. Yet few empirical studies have sought to characterize how and to what extent structural features determine fluency and linguistic quality. We report the results of experiments on the predictive power of syntactic phrasing statistics and other structural features for these aspects of text. Manual assessments of sentence fluency for machine translation evaluation and text quality for summarization evaluation are used as gold-standard. We find that many structural features related to phrase length are weakly but significantly correlated with fluency and classifiers based on the entire suite of structural features can achieve high accuracy in pairwise comparison of sentence fluency and in distinguishing machine translations from human translations. We also test the hypothesis that the learned models capture general fluency properties applicable to human-authored text. The results from our experiments do not support the hypothesis. At the same time structural features and models based on them prove to be robust for automatic evaluation of the linguistic quality of multi-document summaries

Serum α-synuclein and IL-1β are increased and correlated with measures of disease severity in children with epilepsy: potential prognostic biomarkers?

The search for noninvasive biomarkers of neuroinflammation and neurodegeneration has focused on various neurological disorders, including epilepsy. We sought to determine whether α-synuclein and cytokines are correlated with the degree of neuroinflammation and/or neurodegeneration in children with epilepsy and with acquired demyelinating disorders of the central nervous system (CNS), as a prototype of autoimmune neuroinflammatory disorders. We analyzed serum and exosome levels of α-synuclein and serum proinflammatory and anti-inflammatory cytokines among 115 children with epilepsy and 10 acquired demyelinating disorders of the CNS and compared to 146 controls. Patients were enrolled prospectively and blood was obtained from patients within 48 h after acute afebrile seizure attacks or relapse of neurological symptoms. Acquired demyelinating disorders of the CNS include acute disseminated encephalomyelitis, multiple sclerosis, neuromyelitis optica spectrum disorders, and transverse myelitis. The controls were healthy age-matched children. The serum exosomes were extracted with ExoQuick exosome precipitation solution. Serum α-synuclein levels and serum levels of cytokines including IFN-β, IFN-γ, IL-1β, IL-6, IL-10 and TNF-α were measured using single and multiplex ELISA kits. Data were analyzed and compared with measures of disease severity, such as age at disease onset, duration of disease, and numbers of antiepileptic drug in use. Serum α-synuclein levels were significantly increased in patients with epilepsy and acquired demyelinating disorders of the CNS compared to controls (both, p < 0.05) and showed correlation with measures of disease severity both in epilepsy (p < 0.05, r = 0.2132) and in acquired demyelinating disorders of the CNS (p < 0.05, r = 0.5892). Exosome α-synuclein showed a significant correlation with serum α-synuclein (p < 0.0001, r = 0.5915). Serum IL-1β levels were correlated only with the numbers of antiepileptic drug used in children with epilepsy (p < 0.001, r = 0.3428), suggesting drug resistant epilepsy. This is the first study in children demonstrating that serum α-synuclein levels were significantly increased in children with epilepsy and with acquired demyelinating disorders of the CNS and correlated with measures of disease severity. Serum IL-1β levels showed significant correlation only with drug resistance in children with epilepsy. Thus, these data support that serum levels of α-synuclein and IL-1β are potential prognostic biomarkers for disease severity in children with epilepsy. CNS, central nervous system.The analysis of cytokines was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2016R1A2B4009438), the Seoul National University Hospital Research Fund (No. 03–2015-0120), and the analysis of α- synuclein and exosomal analysis were supported by the Seoul National University Boramae Hospital Research Fund (No. 03–2013-8 and 01–2014-11) to JC1. The correlation analysis of cytokines and α-synuclein were supported by grants from the NRF funded by the Korean government (MEST) (No. 2017R1A2B3006704 and 2019R1A6A1A03032869) to JS. The role of the funding bodies is data collection, data analysis and document retrieval

Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients with Glomerulonephritis

Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of renin-angiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality

Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study

Although more than one-third of the patients with acute heart failure (AHF) have diabetes mellitus (DM), it is unclear if DM has an adverse impact on clinical outcomes. This study compared the outcomes in patients hospitalized for AHF stratified by DM and left ventricular ejection fraction (LVEF). The Korean Acute Heart Failure registry prospectively enrolled and followed 5625 patients from March 2011 to February 2019. The primary endpoints were in-hospital and overall all-cause mortality. We evaluated the impact of DM on these endpoints according to HF subtypes and glycemic control. During a median follow-up of 3.5years, there were 235 (4.4%) in-hospital mortalities and 2500 (46.3%) overall mortalities. DM was significantly associated with increased overall mortality after adjusting for potential confounders (adjusted hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.03–1.22). In the subgroup analysis, DM was associated with higher a risk of overall mortality in heart failure with reduced ejection fraction (HFrEF) only (adjusted HR 1.14, 95% CI 1.02–1.27). Inadequate glycemic control (HbA1c ≥ 7.0% within 1year after discharge) was significantly associated with a higher risk of overall mortality compared with adequate glycemic control (HbA1c < 7.0%) (44.0% vs. 36.8%, log-rank p = 0.016). DM is associated with a higher risk of overall mortality in AHF, especially HFrEF. Well-controlled diabetes (HbA1c < 7.0%) is associated with a lower risk of overall mortality compared to uncontrolled diabetes. Trial registration ClinicalTrial.gov, NCT01389843. Registered July 6, 2011. https://clinicaltrials.gov/ct2/show/NCT01389843This study was supported by Research of Korea Centers for Disease Control and Prevention (2010-E63003-00, 2011-E63002-00, 2012-E63005-00, 2013E63003-00, 2013-E63003-01, 2013-E63003-02, and 2016-ER6303-00)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Seasonal changes in surface ozone over South Korea

Recently, the surface ozone concentration in the Korean peninsula has been increasing more rapidly than in the past, and seasonal changes are appearing such as increases in the number of ozone alerts in springtime. We examined changes in the timing of annual maximum South Korean O3 levels by fitting a sine function to data from 54 air-quality monitoring sites over a 10-year period (2005–2014). The analytical results show that the date of maximum ozone concentration at 23 points in the last 10 years has been advanced by about 2.1 days per year (E-sites), while the remaining 31 points have been delayed by about 2.5 days per year (L-sites). We attribute these differences to seasonal O3 changes: E-sites show a larger increase in O3 level in March–April (MA) than in June–July (JJ), while L-sites show a larger increase in JJ than in MA. Furthermore, these shifts are significantly larger in magnitude than those reported for Europe and North America. We also examined one possible reason for these seasonal differences: the relationship between O3 and precursors such as NO2 and CO. E-sites showed a rapid decrease in NO2 (NO) concentration in MA over the last decade. As a result, the ozone concentration at E-sites seems to have increased due to the absence of ozone destruction by NOx titration in early spring. In L-Sites, the concentrations of ozone precursors such as NO2 and CO in JJ showed a smaller decrease than those at other sites. Therefore, in L-sites, relatively large amounts of ozone precursors were distributed in JJ, implying that more ozone was generated. We suggest that shifts in the South Korean O3 seasonal cycle are due to changes in early spring and summer NO2 (NO) and CO levels; this should be tested further by modeling studies

Cross Encoder-Decoder Transformer with Global-Local Visual Extractor for Medical Image Captioning

Transformer-based approaches have shown good results in image captioning tasks. However, current approaches have a limitation in generating text from global features of an entire image. Therefore, we propose novel methods for generating better image captioning as follows: (1) The Global-Local Visual Extractor (GLVE) to capture both global features and local features. (2) The Cross Encoder-Decoder Transformer (CEDT) for injecting multiple-level encoder features into the decoding process. GLVE extracts not only global visual features that can be obtained from an entire image, such as size of organ or bone structure, but also local visual features that can be generated from a local region, such as lesion area. Given an image, CEDT can create a detailed description of the overall features by injecting both low-level and high-level encoder outputs into the decoder. Each method contributes to performance improvement and generates a description such as organ size and bone structure. The proposed model was evaluated on the IU X-ray dataset and achieved better performance than the transformer-based baseline results, by 5.6% in BLEU score, by 0.56% in METEOR, and by 1.98% in ROUGE-L